ArticleExpert review of clinical pharmacology2009
Targeting sigma receptors: novel medication development for drug abuse and addiction.
Article in Expert review of clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- Effects of fenfluramine and sigma-1-dependent pharmacological and genetic modulation in a mouse kindling model.Epilepsia · 2026Article
- Preclinical Profile of CM699 as a Medication Candidate for Stimulant Use Disorder.ACS chemical neuroscience · 2025Article
- Sigma-1 receptor and seizures.Pharmacological research · 2023Review
- Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids.Acta pharmaceutica Sinica. B · 2023Article
- Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain.Molecules (Basel, Switzerland) · 2022Article
- Sigma receptors and neurological disorders.Pharmacological reports : PR · 2021Review
- The Sigma-2 receptor / transmembrane protein 97 (σ2R/TMEM97) modulator JVW-1034 reduces heavy alcohol drinking and associated pain states in male mice.Neuropharmacology · 2021Article
- The Sigma 2 receptor promotes and the Sigma 1 receptor inhibits mu-opioid receptor-mediated antinociception.Molecular brain · 2020Article
- Mitigation of cocaine-mediated mitochondrial damage, defective mitophagy and microglial activation by superoxide dismutase mimetics.Autophagy · 2020Article
- Cocaine Mediated Neuroinflammation: Role of Dysregulated Autophagy in Pericytes.Molecular neurobiology · 2019Article
- Drug abuse and HIV-related pulmonary hypertension: double hit injury.AIDS (London, England) · 2018Review
- Loss of Sigma-1 Receptor Chaperone Promotes Astrocytosis and Enhances the Nrf2 Antioxidant Defense.Oxidative medicine and cellular longevity · 2017Article
- Sigma receptors [σRs]: biology in normal and diseased states.Journal of receptor and signal transduction research · 2016Article
- Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity.Bioorganic & medicinal chemistry · 2016Article
- Mechanisms of activation of nucleus accumbens neurons by cocaine via sigma-1 receptor-inositol 1,4,5-trisphosphate-transient receptor potential canonical channel pathways.Cell calcium · 2015Article
- Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.Drug and alcohol dependence · 2015Review
- The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders.Frontiers in microbiology · 2015Review
- Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist.The Journal of pharmacology and experimental therapeutics · 2014Article
- Stimulants as specific inducers of dopamine-independent σ agonist self-administration in rats.The Journal of pharmacology and experimental therapeutics · 2013Article
- Effect of ring-constrained phenylpropyloxyethylamines on sigma receptors.Bioorganic & medicinal chemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Psychostimulant abuse is a serious health and societal problem in industrialized and developing countries. However, the identification of an effective pharmacotherapy to treat it has remained elusive. It has long been known that many psychostimulant drugs, including cocaine and methamphetamine, interact with sigma receptors in the brain and heart, offering a logical target for medication development efforts. However, selective pharmacological agents and molecular biological tools have only recently become available to rigorously evaluate these receptors as viable medication development targets. The current review will summarize provocative preclinical data, demonstrating the ability of sigma receptor antagonists and antisense oligonucleotides to ameliorate cocaine-induced convulsions, lethality, locomotor activity and sensitization, and conditioned place-preference in rodents. Recent studies suggest that the protective effects of sigma receptor antagonists also extend to actions produced by methamphetamine, 3,4-methylenedioxymethamphetamine, ethanol and other abused substances. Together, the data indicate that targeting sigma receptors, particularly the σ(1)-subtype, may offer an innovative approach for combating the effects of cocaine, and perhaps other abused substances.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.